MedTrace Logo

Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex with Men (DaDHS)

NCT02864550 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-02-12

No results posted yet for this study

Summary

Syphilis is a sexually transmitted infection (STI) disproportionately affecting gay, bisexual and other men who have sex with men (gbMSM), with the potential for significant sequelae - particularly in those who are Human Immunodeficiency Virus (HIV)-positive. Rising rates of this STI have prompted a search for novel prevention solutions. A recent pilot study of daily doxycycline prophylaxis demonstrated promise as a novel STI prevention tool. This innovative approach to STI prevention has solid clinical precedent, both from the HIV pre-exposure prophylaxis (PrEP) literature, as well as doxycycline's use as prophylaxis for other infections. The overarching goal of this project is to determine whether the daily use of doxycycline is an efficacious and acceptable intervention for syphilis prevention in high-risk, HIV-positive gbMSM.

Conditions

  • Syphilis
  • Sexually Transmitted Infections

Interventions

DRUG

Doxycycline

doxycycline 100mg orally daily

OTHER

Placebo

placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group

Sponsors & Collaborators

  • British Columbia Centre for Disease Control

    lead OTHER_GOV

Principal Investigators

  • Troy Grennan, MD · BC Centre for Disease Control

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2024-04-05
Completion
2024-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02864550 on ClinicalTrials.gov